Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
26.04
+0.20 (0.77%)
At close: Nov 18, 2026, 4:00 PM EST
26.24
+0.20 (0.77%)
After-hours: Nov 18, 2026, 5:49 PM EST
Zymeworks Revenue
Zymeworks had revenue of $512.92M in the quarter ending September 30, 2026, with 828.73% growth. This brings the company's total for the last twelve months to $264.61M, up 117.67% year-over-year. In the year 2025, Zymeworks had annual revenue of $105.97M with 38.87% growth. That makes Zymeworks the 15,437th largest company in the world by revenue and 2,684th in the United States.
Revenue (ttm)
$264.61M
Revenue Growth
+117.67%
P/S Ratio
6.72
Revenue / Employee
$953,308
Employees
279
Market Cap
1.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.97M | 29.66M | 38.87% |
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
| Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
| Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
| Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
| Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
| Dec 31, 2014 | 1.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.96B |
| Nurix Therapeutics | 701.94M |
| Vir Biotechnology | 302.80M |
| Agios Pharmaceuticals | 140.84M |
| Mesoblast | 120.25M |
| Stoke Therapeutics | 28.21M |
| Maze Therapeutics | 20.00M |
| Zenas BioPharma | 11.00M |
ZYME News
- 1 day ago - Zymeworks Transcript: Jefferies Global Healthcare Conference - Transcripts
- 2 days ago - Zymeworks management to meet with B. Riley - TheFly
- 2 days ago - Zymeworks announces $200M share repurchase program - TheFly
- 2 days ago - Zymeworks Announces $200 Million Share Repurchase Authorization - GlobeNewsWire
- 5 days ago - Zymeworks price target raised to $39 from $32 at Citizens - TheFly
- 7 days ago - Zymeworks Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 7 days ago - Zymeworks price target raised to $44 from $39 at Citi - TheFly
- 8 days ago - Zymeworks reports Q3 EPS $2.28, consensus $2.19 - TheFly